Analysts See $-0.35 EPS for PTC Therapeutics, Inc. (PTCT)

May 9, 2018 - By Louis Casey

PTC Therapeutics, Inc. (NASDAQ:PTCT) LogoInvestors sentiment decreased to 0.98 in Q4 2017. Its down 0.73, from 1.71 in 2017Q3. It is negative, as 23 investors sold PTC Therapeutics, Inc. shares while 35 reduced holdings. 23 funds opened positions while 34 raised stakes. 35.45 million shares or 7.80% more from 32.89 million shares in 2017Q3 were reported.
Shanda Asset Management accumulated 30,332 shares. Great Point Prtn Limited Com has 3.09% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 1.09M shares. Bnp Paribas Arbitrage Sa holds 8,458 shares. Tiaa Cref Invest Management Limited invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Sectoral Asset owns 372,634 shares for 0.78% of their portfolio. 68,700 are held by Axa. South Dakota Inv Council holds 151,300 shares. Pinnacle Assocs has 289,432 shares. New York-based D E Shaw And has invested 0.06% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Sei holds 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT) or 1,000 shares. Vanguard Gp has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). 1,413 are held by Tower Rech Cap Limited Liability Company (Trc). Tudor Et Al has 27,031 shares. Northern Trust Corp invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Alps Advisors owns 45,975 shares.

Since January 3, 2018, it had 0 insider purchases, and 4 insider sales for $61,523 activity. 2,230 shares valued at $40,207 were sold by Peltz Stuart Walter on Friday, January 5. Almstead Neil Gregory also sold $12,675 worth of PTC Therapeutics, Inc. (NASDAQ:PTCT) shares.

Analysts expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to report $-0.35 EPS on May, 14.They anticipate $0.50 EPS change or 58.82 % from last quarter’s $-0.85 EPS. After having $0.03 EPS previously, PTC Therapeutics, Inc.’s analysts see -1,266.67 % EPS growth. The stock increased 1.65% or $0.5 during the last trading session, reaching $30.74. About 427,221 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 274.65% since May 10, 2017 and is uptrending. It has outperformed by 263.10% the S&P500.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Among 6 analysts covering PTC Therapeutics (NASDAQ:PTCT), 1 have Buy rating, 1 Sell and 4 Hold. Therefore 17% are positive. PTC Therapeutics had 8 analyst reports since November 16, 2017 according to SRatingsIntel. On Thursday, February 22 the stock rating was maintained by Citigroup with “Buy”. The stock has “Underweight” rating by Barclays Capital on Wednesday, April 4. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Hold” rating by J.P. Morgan on Thursday, November 16. The company was maintained on Wednesday, March 7 by RBC Capital Markets. The firm has “Equal-Weight” rating given on Wednesday, March 7 by Barclays Capital. RBC Capital Markets reinitiated PTC Therapeutics, Inc. (NASDAQ:PTCT) on Monday, January 29 with “Hold” rating. The rating was upgraded by JP Morgan to “Neutral” on Thursday, November 16. The firm has “Hold” rating given on Wednesday, April 18 by Cowen & Co.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company has market cap of $1.43 billion. The company's lead product is Translarna , for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It currently has negative earnings. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy.

More recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: Nasdaq.com which released: “Analysis: Positioning to Benefit within Entergy, Schneider National, CH Robinson Worldwide, PTC Therapeutics, Guess …” on May 09, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” on May 09, 2018. Prnewswire.com‘s news article titled: “Biotechnology Companies Making Major Announcements” with publication date: May 03, 2018 was also an interesting one.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: